{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104951",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104951",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for irinotecan and UGT1A1",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450085",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450085",
    "name" : "irinotecan"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA420",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA420",
    "symbol" : "UGT1A1",
    "name" : "UDP glucuronosyltransferase 1 family, polypeptide A1"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>Reduce the starting dose of irinotecan for UGT1A1*28 homozygous patients receiving more than 250 mg/m^2.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend reducing the dose for *28 homozygous patients receiving more than 250 mg/m^2.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> *1/*28 </td><td> None. </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression. </td></tr><tr><td> *28/*28 </td><td> Dose &gt;250mg/m^2: reduce initial dose by 30%. Increase dose in response to neutrophil count.  Dose &lt;=250mg/m^2: no dose adjustment.  </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10^9/l; leucopenia &lt; 1.0x10^9/l; thrombocytopenia &lt; 25x10^9/l; life-threatening complications from diarrhea. </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li></ul>"
}